Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
08 December 2023 | Story Leonie Bolleurs | Photo Charl Devenish
Thabo Dithebe
When Thabo Dithebe walked across the stage in the Callie Human Centre, a childhood dream came true, despite several difficulties he had to deal with during his studies.

Thabo Dithebe received his Bachelor of Management Leadership (BML) qualification during the University of the Free State’s December graduation ceremonies. His life journey of resilience, adaptability, and a willingness to embrace unexpected opportunities is an inspiring story that needs to be told. 

Born in the farming community of Bothaville, Thabo initially wanted to pursue a career in engineering, and he chose maths, science, and technical subjects in high school. However, a temporary job in retail near home and experiencing the toll of retrenchment redirected his path to sales and marketing and pushed him to apply for a BML in the UFS Business School.

“When I enrolled for the BML, my childhood dream of going to university became a reality. Although the journey was not easy, it was worth pursuing,” says Thabo, who is employed as an area sales manager at Marltons Pet Care.

Balancing studies and responsibilities at home

In addition to managing the pressure of being stretched to the limit in class, Thabo also had to balance his studies with the responsibilities at home – taking care of his sick and disabled daughter.

“Balancing these commitments was always a challenge, but I was fortunate to have a supportive caregiver who understood the needs of children living with disabilities. There were tough times, especially during submission seasons when my daughter would fall ill. In those moments, I had to prioritise her health, temporarily setting aside my studies until she received proper care at the hospital,” he states.

Besides caring for his daughter and being retrenched, he also went through a breakup. Thabo believes that things could have turned out differently if he had stopped imagining and dreaming, because he had every reason to give up. He describes reaching this significant milestone in his life as ‘unreal’. 

He says that he was motivated to persevere, because from the first day he enrolled, he wanted to make his family proud of him. “There were times when I asked myself if I had what it takes to complete the programme. Should I choose not to complete the course, what would I say to my son when life knocks him down, when he sees me giving up? How do I face my mother if I came back defeated? I had good people on my side who wanted me to succeed,” he says.

Ready to take on the next challenge

Having reached this significant milestone in his life, Thabo is ready for the next challenge. “I am hoping to be accepted into the PGDip in Business Administration programme for the 2024 intake,” he says. 

He advises others who face challenges while pursuing their educational goals to understand that their situation is not permanent and that there is strength in adversity. “It is important to celebrate the small victories often and to associate yourself with people who work harder than you,” he adds.

On 7 December 2023, as Thabo walked across the stage, he looked for the face of his mother in the audience – a lady who made several sacrifices to raise him and his five siblings. “I hope that when she saw me, she was very proud of me,” he concludes. 

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept